沈杨教授：奎扎替尼率先落地我国瑞金海南医院无疑是一个积极的领域进展。当前，白血病治疗领域正呈现传统化疗与新型靶向治疗药物联合应用的发展趋势，包括诱导治疗与维持治疗阶段。以诱导治疗为例，传统3+7方案已逐步升级为“3+7+X”联合方案，其中“X”包含FLT3抑制剂。在国际上，奎扎替尼作为FLT3抑制剂已被明确列为FLT3-ITD突变阳性AML患者的推荐药物，然而目前国内尚未可及，此次引入直接填补了此 ...

AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...

The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...